Are you over 18 and want to see adult content?
More Annotations
![A complete backup of https://proedinc.com](https://www.archivebay.com/archive6/images/8120cdce-3730-4866-83c8-ca0e62b6c2fb.png)
A complete backup of https://proedinc.com
Are you over 18 and want to see adult content?
![A complete backup of https://tienve.org](https://www.archivebay.com/archive6/images/d2ea01b1-9bfb-4c66-bda1-f953626580e3.png)
A complete backup of https://tienve.org
Are you over 18 and want to see adult content?
![A complete backup of https://codevibrant.com](https://www.archivebay.com/archive6/images/50d9b706-9c0b-456d-8aa3-a662fd925596.png)
A complete backup of https://codevibrant.com
Are you over 18 and want to see adult content?
![A complete backup of https://lararnasnyheter.se](https://www.archivebay.com/archive6/images/1e454cc4-b353-4502-8020-1f2a57b980ec.png)
A complete backup of https://lararnasnyheter.se
Are you over 18 and want to see adult content?
![A complete backup of https://bombtrack.com](https://www.archivebay.com/archive6/images/bad98ff2-d76d-4cd4-a875-1bd3ec5568a1.png)
A complete backup of https://bombtrack.com
Are you over 18 and want to see adult content?
![A complete backup of https://4ride.ru](https://www.archivebay.com/archive6/images/512f0a46-01f3-48c5-819e-e80b2e95ac95.png)
A complete backup of https://4ride.ru
Are you over 18 and want to see adult content?
![A complete backup of https://ukdissertations.net](https://www.archivebay.com/archive6/images/ad6eacb7-3c97-48ed-8eed-655ea0f3dc8e.png)
A complete backup of https://ukdissertations.net
Are you over 18 and want to see adult content?
![A complete backup of https://tierra.net](https://www.archivebay.com/archive6/images/838eb3ef-26c6-4af9-a85e-4c0d97436648.png)
A complete backup of https://tierra.net
Are you over 18 and want to see adult content?
![A complete backup of https://dolore.gq](https://www.archivebay.com/archive6/images/c00183cc-1135-4691-8373-0234c49a4fcc.png)
A complete backup of https://dolore.gq
Are you over 18 and want to see adult content?
![A complete backup of https://bango.com](https://www.archivebay.com/archive6/images/bc919f2f-1e19-41ba-b26f-f453194d2e60.png)
A complete backup of https://bango.com
Are you over 18 and want to see adult content?
![A complete backup of https://industriemagazin.at](https://www.archivebay.com/archive6/images/ef2e07cc-c6ac-4739-8af8-cd25b716f697.png)
A complete backup of https://industriemagazin.at
Are you over 18 and want to see adult content?
![A complete backup of https://allongeorgia.com](https://www.archivebay.com/archive6/images/d65fbe64-b3f2-4c7d-ba60-76b847c4131a.png)
A complete backup of https://allongeorgia.com
Are you over 18 and want to see adult content?
Favourite Annotations
![A complete backup of www.tgcom24.mediaset.it/televisione/la-pupa-e-il-secchione-e-viceversa-aldo-busi-si-commuove-ecco-cos-la-be](https://www.archivebay.com/archive2/914cd6ee-afad-4a1b-a4a4-ba385b42de82.png)
A complete backup of www.tgcom24.mediaset.it/televisione/la-pupa-e-il-secchione-e-viceversa-aldo-busi-si-commuove-ecco-cos-la-be
Are you over 18 and want to see adult content?
![A complete backup of www.polskieradio24.pl/5/1222/Artykul/2453187](https://www.archivebay.com/archive2/01bdaa02-2b56-49e3-b49f-ce90f271e5a6.png)
A complete backup of www.polskieradio24.pl/5/1222/Artykul/2453187
Are you over 18 and want to see adult content?
![A complete backup of www.huffingtonpost.it/entry/quarantanni-fa-lomicidio-di-vittorio-bachelet-mattarella-ucciso-perche-imperson](https://www.archivebay.com/archive2/b951c53d-60b6-4bc6-aabe-de7fc0a92d16.png)
A complete backup of www.huffingtonpost.it/entry/quarantanni-fa-lomicidio-di-vittorio-bachelet-mattarella-ucciso-perche-imperson
Are you over 18 and want to see adult content?
Text
vacation records.
EARLY CLINICAL DRUG DEVELOPMENT GROUP CLINICAL RESEARCH Early Clinical Drug Development Group ELENA GARRALDA Principal Investigator We focus on proof-of-concept and proof-of-mechanism trials with targeted therapies, with particular emphasis on cell signaling, cancer stem cells, and immuno-oncology. These include first-in-human studies of targeted therapies, rationalELENA GARRALDA
Scientific Committees & Advisory Roles. ESMO – Women for Oncology. Committee Member. 2017. Evaluation Committee – CLIPP Labellisation 2019-2024, Institut National de Cancer, Paris. 2018.CÉSAR SERRANO
CÉSAR SERRANO BIOSKETCH Current positions Principal Investigator, Sarcoma Translational Research Group, Vall d’Hebron Institute of Oncology (VHIO). Attending Physician, Genitourinary, CNS and Sarcoma Tumors Program, VHIO. Sarcoma Faculty, European SocietyJOAQUIN MATEO
Current positions. Principal Investigator, Prostate Cancer Translational Research Group, Vall d’Hebron Institute of Oncology (VHIO). Medical Oncologist & Attending Physician, Medical Oncology Department, Vall d’Hebron University Hospital (HUVH).FRANCESC BOSCH
FRANCESC BOSCH fbosch@vhio.net, macrespo@vhio.net Current positions 2016 – Present: Principal Investigator of VHIO´s Experimental Hematology Group 10/2010 – Present: Professor, the Department of Medicine, Universitat Autònoma de Barcelona, Spain 09/2009 – Present: Head, DepartmentANA VIVANCOS
ANA VIVANCOS avivancos@vhio.net Current positions Principal Investigator, Cancer Genomics Group Reviewer for: Clinical Cancer Research, Nature, and Oncogene. Academic Qualifications PhD, Biochemistry and Molecular Biology, Universitat Pompeu Fabra, 2006. Dissertation: Role of the peroxiredoxin Tpx1 and the transcription VHIO - VALL D'HEBRON INSTITUTE OF ONCOLOGY iniciar sesión Copyright © VHIO 2021 VHIO – VALL D'HEBRON INSTITUTE OF ONCOLOGYTRANSLATE THIS PAGE SOBRE EL VHIO El VHIO es un destacado centro oncológico integral de excelencia donde los científicos y doctores adoptan un modelo de investigación puramente traslacional, trabajando conjuntamente en equipos multidisciplinares para acelerar y avanzar en el campo de las terapias personalizadas y específicas contra el cáncer. SABER MÁS VHIO – VALL D'HEBRON INSTITUTE OF ONCOLOGYABOUT VHIOPROGRAMS & GROUPSPRINCIPAL INVESTIGATORSCLINICAL TRIALSPROJECTS & INSTL PROGRAMS VHIO is a leading comprehensive cancer center of excellence where its scientists and physicians adopt a purely translational research model, working together as multidisciplinary teams to both accelerate and advance personalized and targeted therapies against cancer: VHIO - VALL D'HEBRON INSTITUTE OF ONCOLOGY Welcome to VHIO´s Intranet Your very own personal dashboard provides you with confidential files including your salary details and yourvacation records.
EARLY CLINICAL DRUG DEVELOPMENT GROUP CLINICAL RESEARCH Early Clinical Drug Development Group ELENA GARRALDA Principal Investigator We focus on proof-of-concept and proof-of-mechanism trials with targeted therapies, with particular emphasis on cell signaling, cancer stem cells, and immuno-oncology. These include first-in-human studies of targeted therapies, rationalELENA GARRALDA
Scientific Committees & Advisory Roles. ESMO – Women for Oncology. Committee Member. 2017. Evaluation Committee – CLIPP Labellisation 2019-2024, Institut National de Cancer, Paris. 2018.CÉSAR SERRANO
CÉSAR SERRANO BIOSKETCH Current positions Principal Investigator, Sarcoma Translational Research Group, Vall d’Hebron Institute of Oncology (VHIO). Attending Physician, Genitourinary, CNS and Sarcoma Tumors Program, VHIO. Sarcoma Faculty, European SocietyJOAQUIN MATEO
Current positions. Principal Investigator, Prostate Cancer Translational Research Group, Vall d’Hebron Institute of Oncology (VHIO). Medical Oncologist & Attending Physician, Medical Oncology Department, Vall d’Hebron University Hospital (HUVH).FRANCESC BOSCH
FRANCESC BOSCH fbosch@vhio.net, macrespo@vhio.net Current positions 2016 – Present: Principal Investigator of VHIO´s Experimental Hematology Group 10/2010 – Present: Professor, the Department of Medicine, Universitat Autònoma de Barcelona, Spain 09/2009 – Present: Head, DepartmentANA VIVANCOS
ANA VIVANCOS avivancos@vhio.net Current positions Principal Investigator, Cancer Genomics Group Reviewer for: Clinical Cancer Research, Nature, and Oncogene. Academic Qualifications PhD, Biochemistry and Molecular Biology, Universitat Pompeu Fabra, 2006. Dissertation: Role of the peroxiredoxin Tpx1 and the transcription VHIO - VALL D'HEBRON INSTITUTE OF ONCOLOGY iniciar sesión Copyright © VHIO 2021 VHIO – VALL D'HEBRON INSTITUTE OF ONCOLOGYTRANSLATE THIS PAGE SOBRE EL VHIO El VHIO es un destacado centro oncológico integral de excelencia donde los científicos y doctores adoptan un modelo de investigación puramente traslacional, trabajando conjuntamente en equipos multidisciplinares para acelerar y avanzar en el campo de las terapias personalizadas y específicas contra el cáncer. SABER MÁS SPEARHEADING NEXT GENERATION CLINICAL TRIALS: CANCER CORE Incorporating experts from the seven European comprehensive cancer centers belonging to the Cancer Core Europe (CCE) Consortium, along with an additional four non-CCE partners*, the EU-funded, multi-site project CCE Building Data Rich Clinical Trials (CCE-DART), has now launched.; Coordinated by VHIO’s Elena Garralda, CCE-DART seeks to become a groundbreaking example in driving a novel NEWLY APPOINTED ESMO FACULTY: VHIO INVESTIGATORS JOIN In parallel with the European Society for Medical Oncology’s (ESMO) publication of its 2025 Vision, which builds on the core priorities and objectives set out in its Vision 2020, ESMO has finalized its 2021 composition of expert committees and working groups, including newly appointed faculty members across various tumor types.. ESMO’s serving officers, including those who have justFRANCESC BOSCH
FRANCESC BOSCH fbosch@vhio.net, macrespo@vhio.net Current positions 2016 – Present: Principal Investigator of VHIO´s Experimental Hematology Group 10/2010 – Present: Professor, the Department of Medicine, Universitat Autònoma de Barcelona, Spain 09/2009 – Present: Head, Department VHIO - VALL D'HEBRON INSTITUTE OF ONCOLOGY iniciar sesión Copyright © VHIO 2021TERESA MACARULLA
Academic Qualifications. Teresa Macarulla received her medical degree from the Universitat Autònoma de Barcelona, Spain, and carried out her residency at the Department of Medical Oncology at the University Hospital Sant Pau, Universitat Autònoma de Barcelona, and obtained her PhD Degree in Medicine and Surgery at the Universitat Autonoma de Barcelona with “Cum Laude“ in 2015. ANA OAKNIN – VHIO – VALL D'HEBRON INSTITUTE OF ONCOLOGY ANA OAKNIN Current positions Principal Investigator, VHIO´s Gynecological Malignancies Group. Head of Gynecologic Tumors Unit, Medical Oncology Department, the Vall d´Hebron University Hospital (HUVH). Full-time Senior Medical Oncologist & Attending Physician, Medical Oncology Department, the Vall d´Hebron University Hospital (HUVH). Academic Qualifications Degree in Medicine andLAURA SOUCEK
Prizes and Scholarships. As a key opinion leader in Myc and cancer, Laura Soucek was invited to write reviews, be guest editor for a special edition of Current Opinion in Pharmacology, and assemble an updated version of the Springer Nature Methods in Molecular Biology series book on Myc protocols. She has also been appointed as Member of the Scientific Committee of the FERO Foundation, Spain. TREBALLA AMB NOSALTRES Oportunitats laborals Es busquen candidats per a diversos càrrecs en la Fundació Vall d'Hebron Institut d'Oncologia. Els candidats seleccionats duran a terme una recerca independent sobre la gènesi, l'evolució, el pronòstic, la prevenció i el tractament del càncer en sinergia amb els esforços continuats. Ofertes de treball:RODRIGO DIENSTMANN
RODRIGO DIENSTMANN rdienstmann@vhio.net LinkedIn Current positions Principal Investigator, Oncology Data Science (ODysSey) Group Research Scientist, Computational Oncology Group, Sage Bionetworks Active member of the European Society of MedicalPAOLO G. NUCIFORO
PAOLO G. NUCIFORO LinkedIn Current positions Head, Molecular Oncology Group Academic Qualifications 1997 Degree in Medicine and Surgery from the University of Catania (Italy) 2002 Board certification inPathology
VHIO – VALL D'HEBRON INSTITUTE OF ONCOLOGYABOUT VHIOPROGRAMS & GROUPSPRINCIPAL INVESTIGATORSCLINICAL TRIALSPROJECTS & INSTL PROGRAMS VHIO is a leading comprehensive cancer center of excellence where its scientists and physicians adopt a purely translational research model, working together as multidisciplinary teams to both accelerate and advance personalized and targeted therapies against cancer: VHIO - VALL D'HEBRON INSTITUTE OF ONCOLOGY Welcome to VHIO´s Intranet. Your very own personal dashboard provides you with confidential files including your salary details and your vacation records. You can also upload and organize your own documents, create groups with whom you wish to connect, browse up-to-the-minute VHIO news, and access a variety of organizational knowledge andELENA GARRALDA
PubMed PMID: 30327308. Blanca Homet Moreno, Elena Garralda, Ricardo Hitt.Tyrosine kinase inhibitors in treating soft tissue sarcomas: sunitinib in non-GIST sarcomas,Clinical & translational Oncology, Educational Series 2010: 12; 468-472. DOI 10.1007/s12094-010-0539-z. J. Sepulveda and E. Garralda. EARLY CLINICAL DRUG DEVELOPMENT GROUP CLINICAL RESEARCHEarly Clinical Drug Development Group. We focus on proof-of-concept and proof-of-mechanism trials with targeted therapies, with particular emphasis on cell signaling, cancer stem cells, and immuno-oncology. These include first-in-human studies of targeted therapies, rational combinations of targeted therapies,biomarker-driven
VHIO – VALL D'HEBRON INSTITUTE OF ONCOLOGYTRANSLATE THIS PAGE VHIO – Vall d'Hebron Institute of Oncology. Comunicado del Patronato del VHIO. en relación al fallecimiento del Dr. José Baselga. Omomyc, un fármaco desarrollado. en el VHIO, llega al ensayo clínico. Vall d’Hebron desarrolla un método poco invasivo. que permite predecir cómo responderán. las metástasis cerebrales a la inmunoterapia.ANA VIVANCOS
ANA VIVANCOS avivancos@vhio.net Current positions Principal Investigator, Cancer Genomics Group Reviewer for: Clinical Cancer Research, Nature, and Oncogene. Academic Qualifications PhD, Biochemistry and Molecular Biology, Universitat Pompeu Fabra, 2006. Dissertation: Role of the peroxiredoxin Tpx1 and the transcriptionCÉSAR SERRANO
Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients. Clin Cancer Res. 2014 Nov 15;20 (22):5745-5755. George S, Barysauskas C, Serrano C, Oduyebo T,Rauh-Hain JA,
JOAQUIN MATEO
Principal Investigator, Prostate Cancer Translational Research Group, Vall d’Hebron Institute of Oncology (VHIO). Medical Oncologist & Attending Physician, Medical Oncology Department, Vall d’Hebron University Hospital (HUVH). Chair of the European Society for Medical Oncology´s (ESMO) Translational Research and Precision MedicineWorking
VHIO - VALL D'HEBRON INSTITUTE OF ONCOLOGY iniciar sesión Copyright © VHIO 2021ONCOTRIALSTRACK
OncoTrialsTrack. Information displayed in OncoTrialsTrack is constantly updated but specific clinical trial recruitment plans may change on a daily basis. Therefore, clinical trial availability must be confirmed with principal investigators of the site. VHIO – VALL D'HEBRON INSTITUTE OF ONCOLOGYABOUT VHIOPROGRAMS & GROUPSPRINCIPAL INVESTIGATORSCLINICAL TRIALSPROJECTS & INSTL PROGRAMS VHIO is a leading comprehensive cancer center of excellence where its scientists and physicians adopt a purely translational research model, working together as multidisciplinary teams to both accelerate and advance personalized and targeted therapies against cancer: VHIO - VALL D'HEBRON INSTITUTE OF ONCOLOGY Welcome to VHIO´s Intranet. Your very own personal dashboard provides you with confidential files including your salary details and your vacation records. You can also upload and organize your own documents, create groups with whom you wish to connect, browse up-to-the-minute VHIO news, and access a variety of organizational knowledge andELENA GARRALDA
PubMed PMID: 30327308. Blanca Homet Moreno, Elena Garralda, Ricardo Hitt.Tyrosine kinase inhibitors in treating soft tissue sarcomas: sunitinib in non-GIST sarcomas,Clinical & translational Oncology, Educational Series 2010: 12; 468-472. DOI 10.1007/s12094-010-0539-z. J. Sepulveda and E. Garralda. EARLY CLINICAL DRUG DEVELOPMENT GROUP CLINICAL RESEARCHEarly Clinical Drug Development Group. We focus on proof-of-concept and proof-of-mechanism trials with targeted therapies, with particular emphasis on cell signaling, cancer stem cells, and immuno-oncology. These include first-in-human studies of targeted therapies, rational combinations of targeted therapies,biomarker-driven
VHIO – VALL D'HEBRON INSTITUTE OF ONCOLOGYTRANSLATE THIS PAGE VHIO – Vall d'Hebron Institute of Oncology. Comunicado del Patronato del VHIO. en relación al fallecimiento del Dr. José Baselga. Omomyc, un fármaco desarrollado. en el VHIO, llega al ensayo clínico. Vall d’Hebron desarrolla un método poco invasivo. que permite predecir cómo responderán. las metástasis cerebrales a la inmunoterapia.ANA VIVANCOS
ANA VIVANCOS avivancos@vhio.net Current positions Principal Investigator, Cancer Genomics Group Reviewer for: Clinical Cancer Research, Nature, and Oncogene. Academic Qualifications PhD, Biochemistry and Molecular Biology, Universitat Pompeu Fabra, 2006. Dissertation: Role of the peroxiredoxin Tpx1 and the transcriptionCÉSAR SERRANO
Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients. Clin Cancer Res. 2014 Nov 15;20 (22):5745-5755. George S, Barysauskas C, Serrano C, Oduyebo T,Rauh-Hain JA,
JOAQUIN MATEO
Principal Investigator, Prostate Cancer Translational Research Group, Vall d’Hebron Institute of Oncology (VHIO). Medical Oncologist & Attending Physician, Medical Oncology Department, Vall d’Hebron University Hospital (HUVH). Chair of the European Society for Medical Oncology´s (ESMO) Translational Research and Precision MedicineWorking
VHIO - VALL D'HEBRON INSTITUTE OF ONCOLOGY iniciar sesión Copyright © VHIO 2021ONCOTRIALSTRACK
OncoTrialsTrack. Information displayed in OncoTrialsTrack is constantly updated but specific clinical trial recruitment plans may change on a daily basis. Therefore, clinical trial availability must be confirmed with principal investigators of the site. SPEARHEADING NEXT GENERATION CLINICAL TRIALS: CANCER CORE Incorporating experts from the seven European comprehensive cancer centers belonging to the Cancer Core Europe (CCE) Consortium, along with an additional four non-CCE partners*, the EU-funded, multi-site project CCE Building Data Rich Clinical Trials (CCE-DART), has now launched.; Coordinated by VHIO’s Elena Garralda, CCE-DART seeks to become a groundbreaking example in driving a novel NEWLY APPOINTED ESMO FACULTY: VHIO INVESTIGATORS JOIN In parallel with the European Society for Medical Oncology’s (ESMO) publication of its 2025 Vision, which builds on the core priorities and objectives set out in its Vision 2020, ESMO has finalized its 2021 composition of expert committees and working groups, including newly appointed faculty members across various tumor types.. ESMO’s serving officers, including those who have just VHIO – VALL D'HEBRON INSTITUTE OF ONCOLOGYTRANSLATE THIS PAGE VHIO – Vall d'Hebron Institute of Oncology. Comunicado del Patronato del VHIO. en relación al fallecimiento del Dr. José Baselga. Omomyc, un fármaco desarrollado. en el VHIO, llega al ensayo clínico. Vall d’Hebron desarrolla un método poco invasivo. que permite predecir cómo responderán. las metástasis cerebrales a la inmunoterapia. ANA OAKNIN – VHIO – VALL D'HEBRON INSTITUTE OF ONCOLOGY ANA OAKNIN Current positions Principal Investigator, VHIO´s Gynecological Malignancies Group. Head of Gynecologic Tumors Unit, Medical Oncology Department, the Vall d´Hebron University Hospital (HUVH). Full-time Senior Medical Oncologist & Attending Physician, Medical Oncology Department, the Vall d´Hebron University Hospital (HUVH). Academic Qualifications Degree in Medicine and VHIO - VALL D'HEBRON INSTITUTE OF ONCOLOGY iniciar sesión Copyright © VHIO 2021VIOLETA SERRA
Violeta Serra received La Marató funding to investigate mechanisms of resistance to therapy with PARP inhibitors (PARPi). By liquid biopsy, Violeta’s team will aim to establish whether the RAD51 biomarker, that can predict sensitivity to PARPi, can more effectively identifyJOAN SEOANE
JOAN SEOANE jseoane@vhio.net Current positions May 2019- present: Director, co-Preclinical and Translational Research Program, VHIO, Barcelona, Spain. Director of Translational Research at VHIO Head of the Gene Expression and Cancer Laboratory ICREA Research Professor,2004 Member of the
PAOLO G. NUCIFORO
Academic Qualifications. 1997 Degree in Medicine and Surgery from the University of Catania (Italy) 2002 Board certification in Pathology from the University of Milan (Italy) 2003 2005 Research fellow at Firc Institute of Molecular Oncology, Milan. 2005-2007 Molecular Pathology Unit Coordinator at Firc Institute of Molecular Oncology, Milan.OFERTES DE FEINA
CELLEX CENTER C/ Natzaret, 115-117 08035 – BARCELONA – Spain Tel: +34 93 254 34 50 email: info@vhio.netAVISO LEGAL
Dominio: www.vhio.net Titular: Fundació Privada Institut d’Investigació Oncològica de Vall d’Hebron Oficina central: CENTRO CELLEX, C/ Natzaret, 115-117 , 08035 – Barcelona Tel: 93 489 30 21 Fax: 93 489 40 64 E-mail: gerencia@vhio.net Datos registrados: Inscrita en el Registro de Fundaciones 2307 Código de Identificación Fiscal (C.I.F.): G-64384969 Condiciones generales de uso 1 VHIO – VALL D'HEBRON INSTITUTE OF ONCOLOGYABOUT VHIOPROGRAMS & GROUPSPRINCIPAL INVESTIGATORSCLINICAL TRIALSPROJECTS & INSTL PROGRAMSVALL D HEBRON INSTITUTE OF ONCOLOGYVHIO BERKELEY VHIO is a leading comprehensive cancer center of excellence where its scientists and physicians adopt a purely translational research model, working together as multidisciplinary teams to both accelerate and advance personalized and targeted therapies against cancer: VHIO - VALL D'HEBRON INSTITUTE OF ONCOLOGY Welcome to VHIO´s Intranet Your very own personal dashboard provides you with confidential files including your salary details and yourvacation records.
EARLY CLINICAL DRUG DEVELOPMENT GROUP CLINICAL RESEARCH Early Clinical Drug Development Group ELENA GARRALDA Principal Investigator We focus on proof-of-concept and proof-of-mechanism trials with targeted therapies, with particular emphasis on cell signaling, cancer stem cells, and immuno-oncology. These include first-in-human studies of targeted therapies, rationalELENA GARRALDA
Scientific Committees & Advisory Roles. ESMO – Women for Oncology. Committee Member. 2017. Evaluation Committee – CLIPP Labellisation 2019-2024, Institut National de Cancer, Paris. 2018. SPEARHEADING NEXT GENERATION CLINICAL TRIALS: CANCER CORE Incorporating experts from the seven European comprehensive cancer centers belonging to the Cancer Core Europe (CCE) Consortium, along with an additional four non-CCE partners*, the EU-funded, multi-site project CCE Building Data Rich Clinical Trials (CCE-DART), has now launched.; Coordinated by VHIO’s Elena Garralda, CCE-DART seeks to become a groundbreaking example in driving a novelCÉSAR SERRANO
CÉSAR SERRANO BIOSKETCH Current positions Principal Investigator, Sarcoma Translational Research Group, Vall d’Hebron Institute of Oncology (VHIO). Attending Physician, Genitourinary, CNS and Sarcoma Tumors Program, VHIO. Sarcoma Faculty, European SocietyANA VIVANCOS
ANA VIVANCOS avivancos@vhio.net Current positions Principal Investigator, Cancer Genomics Group Reviewer for: Clinical Cancer Research, Nature, and Oncogene. Academic Qualifications PhD, Biochemistry and Molecular Biology, Universitat Pompeu Fabra, 2006. Dissertation: Role of the peroxiredoxin Tpx1 and the transcriptionJOAN CARLES
JOAN CARLES jcarles@vhio.net Current positions Head of the Genitourinary, CNS and Sarcoma Tumors Program. Associate Professor of Medicine at the Autonomous University of Barcelona and Coordinator of the optional subject of Medical Oncology VHIO – VALL D'HEBRON INSTITUTE OF ONCOLOGY SOBRE EL VHIO El VHIO es un destacado centro oncológico integral de excelencia donde los científicos y doctores adoptan un modelo de investigación puramente traslacional, trabajando conjuntamente en equipos multidisciplinares para acelerar y avanzar en el campo de las terapias personalizadas y específicas contra el cáncer. SABER MÁSONCOTRIALSTRACK
Information displayed in OncoTrialsTrack is constantly updated but specific clinical trial recruitment plans may change on a daily basis. Therefore, clinical trial availability must be confirmed with principal investigators of the site. VHIO – VALL D'HEBRON INSTITUTE OF ONCOLOGYABOUT VHIOPROGRAMS & GROUPSPRINCIPAL INVESTIGATORSCLINICAL TRIALSPROJECTS & INSTL PROGRAMSVALL D HEBRON INSTITUTE OF ONCOLOGYVHIO BERKELEY VHIO is a leading comprehensive cancer center of excellence where its scientists and physicians adopt a purely translational research model, working together as multidisciplinary teams to both accelerate and advance personalized and targeted therapies against cancer: VHIO - VALL D'HEBRON INSTITUTE OF ONCOLOGY Welcome to VHIO´s Intranet Your very own personal dashboard provides you with confidential files including your salary details and yourvacation records.
EARLY CLINICAL DRUG DEVELOPMENT GROUP CLINICAL RESEARCH Early Clinical Drug Development Group ELENA GARRALDA Principal Investigator We focus on proof-of-concept and proof-of-mechanism trials with targeted therapies, with particular emphasis on cell signaling, cancer stem cells, and immuno-oncology. These include first-in-human studies of targeted therapies, rationalELENA GARRALDA
Scientific Committees & Advisory Roles. ESMO – Women for Oncology. Committee Member. 2017. Evaluation Committee – CLIPP Labellisation 2019-2024, Institut National de Cancer, Paris. 2018. SPEARHEADING NEXT GENERATION CLINICAL TRIALS: CANCER CORE Incorporating experts from the seven European comprehensive cancer centers belonging to the Cancer Core Europe (CCE) Consortium, along with an additional four non-CCE partners*, the EU-funded, multi-site project CCE Building Data Rich Clinical Trials (CCE-DART), has now launched.; Coordinated by VHIO’s Elena Garralda, CCE-DART seeks to become a groundbreaking example in driving a novelCÉSAR SERRANO
CÉSAR SERRANO BIOSKETCH Current positions Principal Investigator, Sarcoma Translational Research Group, Vall d’Hebron Institute of Oncology (VHIO). Attending Physician, Genitourinary, CNS and Sarcoma Tumors Program, VHIO. Sarcoma Faculty, European SocietyANA VIVANCOS
ANA VIVANCOS avivancos@vhio.net Current positions Principal Investigator, Cancer Genomics Group Reviewer for: Clinical Cancer Research, Nature, and Oncogene. Academic Qualifications PhD, Biochemistry and Molecular Biology, Universitat Pompeu Fabra, 2006. Dissertation: Role of the peroxiredoxin Tpx1 and the transcriptionJOAN CARLES
JOAN CARLES jcarles@vhio.net Current positions Head of the Genitourinary, CNS and Sarcoma Tumors Program. Associate Professor of Medicine at the Autonomous University of Barcelona and Coordinator of the optional subject of Medical Oncology VHIO – VALL D'HEBRON INSTITUTE OF ONCOLOGY SOBRE EL VHIO El VHIO es un destacado centro oncológico integral de excelencia donde los científicos y doctores adoptan un modelo de investigación puramente traslacional, trabajando conjuntamente en equipos multidisciplinares para acelerar y avanzar en el campo de las terapias personalizadas y específicas contra el cáncer. SABER MÁSONCOTRIALSTRACK
Information displayed in OncoTrialsTrack is constantly updated but specific clinical trial recruitment plans may change on a daily basis. Therefore, clinical trial availability must be confirmed with principal investigators of the site. NEWS – VHIO – VALL D'HEBRON INSTITUTE OF ONCOLOGY CELLEX CENTER C/ Natzaret, 115-117 08035 – BARCELONA – Spain Tel: +34 93 254 34 50 email: info@vhio.netJOAN CARLES
JOAN CARLES jcarles@vhio.net Current positions Head of the Genitourinary, CNS and Sarcoma Tumors Program. Associate Professor of Medicine at the Autonomous University of Barcelona and Coordinator of the optional subject of Medical OncologyFRANCESC BOSCH
FRANCESC BOSCH fbosch@vhio.net, macrespo@vhio.net Current positions 2016 – Present: Principal Investigator of VHIO´s Experimental Hematology Group 10/2010 – Present: Professor, the Department of Medicine, Universitat Autònoma de Barcelona, Spain 09/2009 – Present: Head, Department VHIO - VALL D'HEBRON INSTITUTE OF ONCOLOGY iniciar sesión Copyright © VHIO 2021 RAQUEL PÉREZ-LÓPEZ Academic Qualifications. 2017: PhD in Medicine at the Universitat Autonoma de Barcelona, Barcelona (Spain).; 2013-2017: Clinical Research Fellowship at the Royal Marsden NHS Trust and the Institute of Cancer Research, London (United Kingdom). ASCO PLENARY: PARPI PREVENTS DISEASE RECURRENCE IN BRCA Full results from the OlympiA Phase III, multicenter trial promise to extend the use of PARPi olaparib as adjuvant therapy for patients with early-stage, high-risk breast cancer with a germline BR ANA OAKNIN – VHIO – VALL D'HEBRON INSTITUTE OF ONCOLOGY ANA OAKNIN Current positions Principal Investigator, VHIO´s Gynecological Malignancies Group. Head of Gynecologic Tumors Unit, Medical Oncology Department, the Vall d´Hebron University Hospital (HUVH). Full-time Senior Medical Oncologist & Attending Physician, Medical Oncology Department, the Vall d´Hebron University Hospital (HUVH). Academic Qualifications Degree in Medicine andRODRIGO DIENSTMANN
RODRIGO DIENSTMANN rdienstmann@vhio.net LinkedIn Current positions Principal Investigator, Oncology Data Science (ODysSey) Group Research Scientist, Computational Oncology Group, Sage Bionetworks Active member of the European Society of MedicalJUDITH BALMAÑA
Most relevant scientific publications. Montalban G, Bonache S, Moles-Fernández A, Gisbert-Beamud A, Tenés A, Bach V, Carrasco E, López-Fernández A, Stjepanovic N, Balmaña J, Diez O, Gutiérrez-Enríquez S. Screening of BRCA1/2 deep intronic regions by targeted gene sequencing identifies the first germline BRCA1 variant causing pseudoexon activation in a patient with breast/ovarian cancer.ONCOTRIALSTRACK
Information displayed in OncoTrialsTrack is constantly updated but specific clinical trial recruitment plans may change on a daily basis. Therefore, clinical trial availability must be confirmed with principal investigators of the site.Accept
This website uses cookies to ensure you get the best experience on ourwebsite More info
Cookie Consent plugin for the EU cookie law Toggle SlidingBar Area* INTRANET
* WEBMAIL
* Language:
* Catal
* Castellano
* English
* INTRANET
* WEBMAIL
* Language:
* Catal
* Castellano
* English
TRANSLATION TOWARD
PRECISION ONCOLOGY
* About Vhio
* WHO WE ARE
* ORGANIZATION
* TRUSTEES
* SCIENTIFIC REPORTS* WORK WITH US
* QUALITY ASSURANCE
* HRS4R
* VALL D’HEBRON UNIVERSITY HOSPITAL* CORPORATE VIDEO
* Programs & Groups
* PRECLINICAL & TRANSLATIONAL RESEARCH* CLINICAL RESEARCH
* CORE TECHNOLOGIES
* Principal Investigators* MARÍA ABAD
* JOAQUIN ARRIBAS
* JUDITH BALMAÑA
* FRANCESC BOSCH
* FRANCESC CANALS
* JOAN CARLES
* RODRIGO DIENSTMANN* ENRIQUETA FELIP
* ELENA GARRALDA
* JORDI GIRALT
* ALENA GROS
* TERESA MACARULLA
* JOAQUIN MATEO
* PAOLO G. NUCIFORO
* ANA OAKNIN
* HÉCTOR G. PALMER
* SANDRA PEIRÓ
* RAQUEL PEREZ-LOPEZ* CRISTINA SAURA
* JOAN SEOANE
* VIOLETA SERRA
* CÉSAR SERRANO
* LAURA SOUCEK
* JOSEP TABERNERO
* JOSEP VILLANUEVA
* ANA VIVANCOS
* Clinical trials
* CLINICAL TRIALS AT VHIO * CLINICAL TRIALS OFFICE * RESEARCH UNIT FOR MOLECULAR THERAPY OF CANCER “LA CAIXA” * CURRENTLY OPEN TRIALS * CLINICAL RESEARCH ONCOLOGY NURSES * CLINICAL RESEARCH ONCOLOGY PHARMACY UNIT * PROJECTS & INSTL PROGRAMS * SCIENTIFIC COORDINATION AREA* CURRENT PROJECTS
* FERO FOUNDATION’s ADVANCED MOLECULAR DIAGNOSTICS PROGRAM * BBVA FOUNDATION’S IMMUNOTHERAPY & IMMUNOLOGY PROGRAM (CAIMI) * “LA CAIXA” INTL RESEARCH & EDUCATION PROGRAM * FUNDING, CONSORTIA & ACCREDITATION* CONTACT US
* News
* Events
* VHIO – ”la Caixa” SCIENTIFIC SEMINARS SERIES * Symposia & Conferences * VHIO _MEET THE EDITORS_ * Workshops & Courses * BENCHSTORMING SEMINARS* Media
* VHIO IN THE MEDIA
* SCIENTIFIC REPORTS* About Vhio
* WHO WE ARE
* ORGANIZATION
* TRUSTEES
* SCIENTIFIC REPORTS* WORK WITH US
* QUALITY ASSURANCE
* HRS4R
* VALL D’HEBRON UNIVERSITY HOSPITAL* CORPORATE VIDEO
* Programs & Groups
* PRECLINICAL & TRANSLATIONAL RESEARCH* CLINICAL RESEARCH
* CORE TECHNOLOGIES
* Principal Investigators* MARÍA ABAD
* JOAQUIN ARRIBAS
* JUDITH BALMAÑA
* FRANCESC BOSCH
* FRANCESC CANALS
* JOAN CARLES
* RODRIGO DIENSTMANN* ENRIQUETA FELIP
* ELENA GARRALDA
* JORDI GIRALT
* ALENA GROS
* TERESA MACARULLA
* JOAQUIN MATEO
* PAOLO G. NUCIFORO
* ANA OAKNIN
* HÉCTOR G. PALMER
* SANDRA PEIRÓ
* RAQUEL PEREZ-LOPEZ* CRISTINA SAURA
* JOAN SEOANE
* VIOLETA SERRA
* CÉSAR SERRANO
* LAURA SOUCEK
* JOSEP TABERNERO
* JOSEP VILLANUEVA
* ANA VIVANCOS
* Clinical trials
* CLINICAL TRIALS AT VHIO * CLINICAL TRIALS OFFICE * RESEARCH UNIT FOR MOLECULAR THERAPY OF CANCER “LA CAIXA” * CURRENTLY OPEN TRIALS * CLINICAL RESEARCH ONCOLOGY NURSES * CLINICAL RESEARCH ONCOLOGY PHARMACY UNIT * PROJECTS & INSTL PROGRAMS * SCIENTIFIC COORDINATION AREA* CURRENT PROJECTS
* FERO FOUNDATION’s ADVANCED MOLECULAR DIAGNOSTICS PROGRAM * BBVA FOUNDATION’S IMMUNOTHERAPY & IMMUNOLOGY PROGRAM (CAIMI) * “LA CAIXA” INTL RESEARCH & EDUCATION PROGRAM * FUNDING, CONSORTIA & ACCREDITATION* CONTACT US
* News
* Events
* VHIO – ”la Caixa” SCIENTIFIC SEMINARS SERIES * Symposia & Conferences * VHIO _MEET THE EDITORS_ * Workshops & Courses * BENCHSTORMING SEMINARS* Media
* VHIO IN THE MEDIA
* SCIENTIFIC REPORTS*
Integrating Genomics and Transcriptomics to reshapePrecision Oncology:
a
Win
ning strategy
*
VHIO-“la Caixa”
Advanced Oncology Research Program: accelerating progress and pushing boundaries in precision oncology*
World Cancer Day 2020: International survey reveals unacceptable cancer awareness divide*
PI3K blockade in HR-positive breast cancer: the ringing in of a more precise and potent clinical futureABOUT VHIO
VHIO is a leading comprehensive cancer center of excellence where its scientists and physicians adopt a purely translational research model, working together as multidisciplinary teams to both accelerate and advance personalized and targeted therapies against cancer:DISCOVER MORE
PROGRAMS & GROUPS
Scientific activity at VHIO is structured across for major programs: Preclinical, Translational, Clinical Research, and Core Technologies. Each incorporates research teams of excellence dedicated to harnessing and rapidly translating discoveries into tangible benefits forpatients.
MEET VHIO´S TEAMS
NEWS
*
*
*
VHIO-“LA CAIXA” ADVANCED ONCOLOGY RESEARCH PROGRAM: ACCELERATING PROGRESS AND PUSHING BOUNDARIES IN PRECISION ONCOLOGY 14/02/2020|Comments Off on VHIO-“la Caixa” Advanced Oncology Research Program: accelerating progress and pushing boundaries inprecision oncology
*
*
*
ADVANCES AND NEW HORIZONS IN THE DIAGNOSIS AND TREATMENT OF COLORECTALCANCER
10/02/2020|Comments Off on Advances and new horizons in the diagnosis and treatment of colorectal cancer*
*
*
WORLD CANCER DAY 2020: INTERNATIONAL SURVEY REVEALS UNACCEPTABLE CANCER AWARENESS DIVIDE 04/02/2020|Comments Off on World Cancer Day 2020: International survey reveals unacceptable cancer awareness divide*
*
*
WORLD CANCER DAY’S CALL TO ACT FOR A CANCER-FREE WORLD: WHAT WILL YOU PLEDGE TO HELP REDUCE THE GLOBAL BURDEN OF DISEASE? 03/02/2020|Comments Off on World Cancer Day’s call to act for a cancer-free world: what will you pledge to help reduce the globalburden of disease?
*
*
*
MARKING JANUARY’S CERVICAL CANCER AWARENESS MONTH: ANA OAKNIN ON ACTIONS AND ADVANCES AGAINST THIS DISEASE 21/01/2020|Comments Off on Marking January’s Cervical Cancer Awareness Month: Ana Oaknin on actions and advances against thisdisease
*
*
*
PI3K BLOCKADE IN HR-POSITIVE BREAST CANCER: THE RINGING IN OF A MORE PRECISE AND POTENT CLINICAL FUTURE 09/01/2020|Comments Off on PI3K blockade in HR-positive breast cancer: the ringing in of a more precise and potent clinical futureSEE ALL NEWS
FOLLOW US:
DIRECTION &
PRINCIPAL INVESTIGATORS*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
Research at VHIO is led by our Director, Josep Tabernero, and supported by a consultative body, VHIO’s Scientific Committee. A total of 26 renowned Principal Investigators manage and run VHIO’s major research themes and programs.BROWSE OUR PIS
SCIENTIFIC
REPORT
2018
LAUNCH
CLINICAL TRIALS
Driving drug development & targeted therapies against cancer, VHIO has become a leading reference in drug discovery from concept to clinic: CLINICAL TRIALS OFFICE RESEARCH UNIT FOR MOLECULAR THERAPY OF CANCER – “LA CAIXA” CURRENTLY OPEN TRIALS*
*
*
*
*
*
PROJECTS & INSTITUTIONAL PROGRAMS Research at VHIO is made possible through the support received from private institutions, funding entities, companies and individuals, as well as International and National Competitive Grants. Find out more about our supporters, current projects and VHIO´s ScientificCoordination Area:
CURRENT PROJECTS
FERO FOUNDATION’S ADVANCED MOLECULAR DIAGNOSTICS PROGRAM BBVA FOUNDATION’S IMMUNOTHERAPY & IMMUNOLOGY PROGRAM (CAIMI) “LA CAIXA” INTL RESEARCH & EDUCATION PROGRAM SCIENTIFIC COORDINATION*
*
EVENTS
VHIO organizes symposia of excellence and ad-hoc courses & workshops through which it shares its expertise and promotes debate and exchange of the highest degree: VHIO – ”LA CAIXA” SCIENTIFIC SEMINARS SERIES INTERNATIONAL SYMPOSIAWORKSHOPS & COURSES
BENCHSTORMING SEMINARS*
*
*
*
CELLEX CENTER
C/ Natzaret, 115-117 08035 - BARCELONA - Spain Tel: +34 93 254 34 50 email: info@vhio.net* CONTACT
* RSS
* TRANSPARENCY PORTAL* LEGAL ADVICE
Vall d'Hebron Institute of Oncology (VHIO)Go to Top
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0